We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Evaluated For Tularemia Diagnosis

By LabMedica International staff writers
Posted on 12 Sep 2012
Print article
The laboratory diagnosis of tularemia is usually based on direct detection of the bacteria either by culture or by nucleic acid amplification techniques and on detection of elevated antibody titers.

A simple, rapid, and affordable point-of-care immunochromatographic assay has been evaluated that may assist in narrowing the differential diagnosis and would be useful for early diagnosis and treatment and for public health surveillance.

Scientists at Public Health Institution (Ankara, Turkey) tested a panel of 221 sera from 109 cases of tularemia as well as 236 sera from normal individuals or individuals with other infectious or autoimmune diseases. A commercially available immunochromatographic assay (ICA) for the serologic diagnosis of tularemia was evaluated, and the performance was compared with that of the current standard, the microagglutination test (MAT).

The VIRapid Tularemia ICA (Vircell; Granada, Spain) was manufactured using lipopolysaccharides (LPS) extracted by the hot phenol–water method from Francisella tularensis cell suspension. LPS was adsorbed on both the conjugate and the test line to generate a lateral flow ICA. A control line was also included to check the correct performance of the test. The test was performed by the addition of serum to the sample pad of the assay device followed by the addition of running fluid. Test results were read after 15 minutes by visual inspection for staining of the antigen and control lines. The intensity of staining of the reaction band was read visually and scored from one to three with a color reference diagram.

The ICA demonstrated 91.5% agreement with the MAT reference method and gave an overall sensitivity of 99.3% and a specificity of 94.6%. When only acute-phase sera were considered, the sensitivity and specificity of the ICA were 100% and 95.5%, respectively. No cross-reactivity was observed in the ICA with serum samples from normal individuals and patients with autoimmune diseases and bacterial, viral, and parasitic infections, although 4 out of 50 patients with brucellosis demonstrated positive results in the ICA.

The authors concluded that ICA showed higher positivity with early acute-phase sera than the reference MAT, while retaining high specificity. The assay should greatly improve the rapid detection of tularemia in the field and facilitate the rapid determination of the extent of public health threat especially in outbreak situations. Tularemia is an infection caused by F. tularensis, a Gram-negative, nonmotile coccobacillus, with a worldwide distribution in the northern hemisphere and diverse clinical manifestations. Humans become infected through arthropod bites, handling of infected animal tissues, or ingestion of contaminated water or food, and inhalation of infectious aerosols. The study was published in the September 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Public Health Institution of Turkey
Vircell


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.